Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R...
ALNY Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced +44.76% Alnylam Pharmaceuticals, Inc. price and volume Combination chart with 2 data series. Chart represents Alnylam Pharmaceuticals, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The...
Earnings estimates and surprises for Alnylam Pharmaceuticals (ALNY) are an important tool used to evaluate the company's overall strength and value of the stock.
Alnylam Pharmaceuticals, Inc. Price Alnylam Pharmaceuticals, Inc. Price|Alnylam Pharmaceuticals, Inc. Quote Zacks Rank & Stocks to Consider Alnylam is a Zacks Rank #4 (Sell) stock. Some better-ranked stocks worth considering are Bristol-Myers Squibb CompanyBMY, Gilead Sciences Inc.GILDand Merck...
AboutAlnylam Pharmaceuticals Alnylam(Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winn...
Alnylam Pharmaceuticals(Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeu...
Alnylam Pharmaceuticals today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2021 and reviewed recent business highlights. Feb. 10, 2022 13:00 UTC − Achieved Fourth Quarter and Full Year 2021 Global...
ALNYLAM PHARMACEUTICALS, INC. 4,736,842 Shares of Common Stock Underwriting Agreement filed by Alnylam Pharmaceuticals, Inc. on January 26th, 2015
ALNYLAM PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts) December 31, 2022 December 31, 2021 ASSETS Current assets: Cash and cash equivalents $ 866,394 $ 819,975 Marketable debt securities 1,297,890 1,548,617 Marketable equity securities 28...
Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote as well as historical stock price data.